Comparative efficacy and bioavailability of different praziquantel brands

Experimental Parasitology

Volumn 127, Issue 2, 2011, Pages 515-521

  Botros, Sanaa ^a   El Lakkany, Naglaa ^a   Seif el Din, Sayed H ^a   Sabra, Abdel Nasser ^a   Ibrahim, Magda ^b  

^a Giza   (Egypt)

^b Department of Research and Quality Control   (Egypt)

Author keywords

Bioavailability; Cytochrome P450 enzymes; Drug metabolism; Physicochemical properties; Praziquantel; Schistosoma mansoni

Indexed keywords

BILHARZID; CYTOCHROME B5; CYTOCHROME P450; EPIQUANTEL; HEXACHLOROPHENE; PRAZIQUANTEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; LIVER LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARASITE CONTROL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE;

ANIMALS; ANTHELMINTICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; HALF-LIFE; MALE; MICE; MICROSOMES, LIVER; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

MUS; SCHISTOSOMA MANSONI;

EID: 78751582029     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.10.019     Document Type: Article

References (30)

1. Akbarieh M., Besner J.G., Galal A., Tawashi R. Liposomal system for the targeting and controlled release of praziquantel. Drug Development and Industrial Pharmacy 1992, 18:303-317.
2. Andrews P. Pharmacokinetic studies with Droncit in animals using a biological assay. Veterinary Medical Review 1976, 2(76):154-165. (English Edition).
3. Appleton C., Mbaye A. Praziquantel-quality, dosages and markers of resistance. Trends in Parasitology 2001, 17:356-357.
4. Badawi A.F., Mostafa M.H. Possible mechanisms of alteration in the capacity of carcinogen-metabolizing enzymes during schistosomiasis. The Journal of International Medical Research 1993, 21:281-305.
5. Becket G., Schep L.J., Tan M.Y. Improvement of the in vitro dissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins. International Journal of Pharmaceutics 1999, 179:65-71.
6. Botros S., Sayed H., Amer N., El-Ghannam M., Bennett J.L., Day T.A. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. International Journal for Parasitology 2005, 35:787-791.
7. Cioli D. Praziquantel: is there real resistance and are there alternatives?. Current Opinion in Infectious Diseases 2000, 13:659-663.
8. Cioli D., Pica-Mattoccia L. Praziquantel. Parasitology Research 2002, 90:S3-S9.
9. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Current Opinion in Infectious Diseases 2008, 21:659-667.
10. Doenhoff M.J., Hagan P., Cioli D., Southgate V., Pica-Mattoccia L., Botros S., Coles G., Tchuem Tchuenté L.A., Mbaye A., Engels D. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009, 136:1825-1835.
11. Duvall R.H., De Witt W.B. Technique for recovering adult schistosomes from laboratory animals. American Journal of Tropical Medicine and Hygiene 1967, 16:438-486.
12. Ebeid F.A., Seif el-Din S.H., Ezzat A.R. Effect of Schistosoma mansoni infection and treatment on drug-metabolizing enzymes. Arzneimittelforschung 2000, 50:867-874.
13. El-Arini S.K., Leuenberger H. Dissolution properties of praziquantel-PVP systems. Pharmaceutica Acta Helvetiae 1998, 73:89-94.
14. El-Guiniady M.A., El-Touny M.A., Abdel-Bary M.A., Abdel-Fatah S.A., Metwally A.A. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. American Journal of Tropical Medicine and Hygiene 1994, 51:809-818.
15. El-Lakkany N.M., Seif el-Din S.H., Badawy A.A., Ebeid F.A. Effect of artemether alone and in combination with grapefruit juice on hepatic drug metabolizing enzymes and biochemical aspects in experimental Schistosoma mansoni. International Journal for Parasitology 2004, 34:1405-1412.
16. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker Inc., New York. second ed.
17. Gonnert R., Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Zeitschrift fur parasitenkund 1977, 52:129-150.
18. Ismail M.M., Metwally A.A., Farghally A., Bruce J.I., Tao L.F., Bennett J.L. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. American Journal of Tropical Medicine and Hygiene 1996, 55:214-218.
19. Kaojarern S., Nathakarnkikool S., Suvanakoot U. Comparative bioavailability of praziquantel tablets. The Annals of Pharmacotherapy 1989, 23:29-32.
20. Leopold G., Ungethum W., Groll E., Diekmann H.W., Nowak H., Wegner D.H. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. European Journal of Clinical Pharmacology 1978, 14:281-291.
21. Liang Y.S., John B.I., Boyd D.A. Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proceeding of the 1st Sino-American Symposium 1987, 1:34-48.
22. Lowry O.H., Rosebrough N.J., Farry A.L., Randall R.J. Protein measurement with Folin-phenol reagent. The Journal of Biological Chemistry 1951, 193:265-275.
23. Metwally A.A. Pharmacokinetics of praziquantel in schistosomiasis patients. Egyptian Journal of Bilharziasis 1989, 11:133-143.
24. Metwally A.A., Bennett J.L., Botros S., Ebeid F., El-Attar G. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacological Research 1995, 31:53-59.
25. Netter K.J. A method for the direct measurement of O-demethylation in liver microsomes and its use in studying microsome inhibition by SKF-525-A. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 1960, 238:292-300.
26. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomesI- Evidence for its haemoprotein nature. The Journal of Biological Chemistry 1964, 239:2370-2378.
27. Sheweita S.A., Mangoura S.A., El-Shemi A.G. Different levels of Schistosoma mansoni infection induced changes in drug-metabolizing enzymes. Journal of Helminthology 1998, 72:71-77.
28. Sulaiman S.M., Traoré M., Engels D., Hagan P., Cioli D. Counterfeit praziquantel. Lancet 2001, 358:666-667.
29. William S., Botros S., Ismail M., Farghally A., Day T.A., Bennett J.L. Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections. Parasitology 2001, 122:63-66.
30. Xiao S.H., Catto B.A., Webster L.T. Quantitative determination of praziquantel in serum by high performance liquid chromatography. Journal of Chromatography 1983, 275:127-132.